Preamble
The American College of Cardiology (ACC) and the American Heart Association (AHA) are committed to the prevention and management of cardiovascular diseases through professional education and research for clinicians, providers, and patients. Since 1980, the ACC and AHA have shared a responsibility to translate scientific evidence into clinical practice guidelines (CPGs) with recommendations to standardize and improve cardiovascular health. These CPGs, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality cardiovascular care.
In response to published reports from the Institute of Medicine 1,2 and the ACC/AHA's mandate to evaluate new knowledge and maintain relevance at the point of care, the ACC/AHA Task Force on Practice Guidelines (Task Force) began modifying its methodology. This modernization effort is published in the 2012 Methodology Summit Report 3 and 2014 perspective article. 4 The latter recounts the history of the collaboration, changes over time, current policies, and planned initiatives to meet the needs of an evolving healthcare environment. Recommendations on value in proportion to resource utilization will be incorporated as high-quality comparative-effectiveness data become available. 5 The relationships between CPGs and data standards, appropriate use criteria, and performance measures are addressed elsewhere. 4 Intended Use-CPGs provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but CPGs developed in collaboration with other organizations may have a broader target. Although CPGs may be used to inform regulatory or payer decisions, the intent is to improve the quality of care and be aligned with the patient's best interest.
Evidence Review-Guideline writing committee (GWC) members are charged with reviewing the literature; weighing the strength and quality of evidence for or against particular tests, treatments, or procedures; and estimating expected health outcomes when data exist. In analyzing the data and developing CPGs, the GWC uses evidence-based methodologies developed by the Task Force. 6 A key component of the ACC/AHA CPG methodology is the development of recommendations on the basis of all available evidence. Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only selected references are cited in the CPG. To ensure that CPGs remain current, new data are reviewed biannually by the GWCs and the Task Force to determine if recommendations should be updated or modified. In general, a target cycle of 5 years is planned for full revisions. 1 Guideline-Directed Medical Therapy-Recognizing advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force designated the term "guidelinedirected medical therapy" (GDMT) to represent recommended medical therapy as defined mainly by Class I measures, generally a combination of lifestyle modification and drug-and device-based therapeutics. As medical science advances, GDMT evolves, and hence GDMT is preferred to "optimal medical therapy." For GDMT and all other recommended drug treatment regimens, the reader should confirm the dosage with product insert material and carefully evaluate for contraindications and possible drug interactions. Recommendations are limited to treatments, drugs, and devices approved for clinical use in the United States.
Class of Recommendation and Level of Evidence-Once recommendations are written, the Class of Recommendation (COR; ie, the strength the GWC assigns to the recommendation, which encompasses the anticipated magnitude and judged certainty of benefit in proportion to risk) is assigned by the GWC. Concurrently, the Level of Evidence (LOE) rates the scientific evidence supporting the effect of the intervention on the basis on the type, quality, quantity, and consistency of data from clinical trials and other reports ( Table 1 ). 4 Unless otherwise stated, recommendations are presented in order by the COR and then the LOE. Where comparative data exist, preferred strategies take precedence. When more than 1 drug, strategy, or therapy exists within the same COR and LOE and there are no comparative data, options are listed alphabetically.
Relationships With Industry and Other Entities-The ACC and AHA exclusively sponsor the work of GWCs without commercial support, and members volunteer their time for this activity. The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that might arise through relationships with industry or other entities (RWI). All GWC members and reviewers are required to fully disclose current industry relationships or personal interests from 12 months before initiation of the writing effort. Management of RWI involves selecting a balanced GWC and requires that both the chair and a majority of GWC members have no relevant RWI (see Appendix 1 for the definition of relevance). GWC members are restricted with regard to writing or voting on sections to which their RWI apply. In addition, for transparency, GWC members' comprehensive disclosure information is available as an online supplement. Comprehensive disclosure information for the Task Force is available as an additional supplement. The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds representing different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. Selected organizations and professional societies with related interests and expertise are invited to participate as partners or collaborators.
Individualizing Care in Patients With Associated Conditions and Comorbidities-The ACC and AHA recognize the complexity of managing patients with multiple conditions, compared with managing patients with a single disease, and the challenge is compounded when CPGs for evaluation or treatment of several coexisting illnesses are discordant or interacting. 7 CPGs attempt to define practices that meet the needs of patients in most, but not all, circumstances and do not replace clinical judgment.
Clinical Implementation-Management in accordance with CPG recommendations is effective only when followed; therefore, to enhance their commitment to treatment and compliance with lifestyle adjustment, clinicians should engage the patient to participate in selecting interventions on the basis of the patient's individual values and preferences, taking associated conditions and comorbidities into consideration (eg, shared decision making). Consequently, there are circumstances in which deviations from these guidelines are appropriate.
The recommendations in this CPG are the official policy of the ACC and AHA until they are superseded by a published addendum, focused update, or revised full-text CPG. The reader is encouraged to consult the full-text CPG 8 for additional guidance and details about the management of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) because the executive summary contains mainly the recommendations.
Jeffrey L. Anderson, MD, FACC, FAHA Chair, ACC/AHA Task Force on Practice Guidelines 1. Introduction
Methodology and Evidence Review
The recommendations listed in this CPG are, whenever possible, evidence based. An extensive evidence review was conducted through October 2012, and other selected references published through April 2014 were reviewed by the GWC. Literature included was derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality Reports, and other selected databases relevant to this CPG. The relevant data are included in evidence tables in the Online Data Supplement. Key search words included but were not limited to the following: acute Table 1 
. Applying Classification of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the clinical practice guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and Ma; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
Organization of the GWC
The GWC was composed of clinicians, cardiologists, internists, interventionists, surgeons, emergency medicine specialists, family practitioners, and geriatricians. The GWC included representatives from the ACC and AHA, American Academy of Family Physicians, American College of Emergency Physicians, American College of Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
Document Review and Approval
This document was reviewed by 2 official reviewers each nominated by the ACC and AHA; 1 reviewer each from the American Academy of Family Physicians, American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons; and 37 individual content reviewers (including members of the American Association of Clinical Chemistry, ACC Heart Failure and Transplant Section Leadership Council, ACC Cardiovascular Imaging Section Leadership Council, ACC Interventional Section Leadership Council, ACC Prevention of Cardiovascular Disease Committee, ACC Surgeons' Council, Association of International Governors, and Department of Health and Human Services). Reviewers' RWI information was distributed to the GWC and is published in this document (Appendix 2).
This document was approved for publication by the governing bodies of the ACC and the AHA and endorsed by the American Association for Clinical Chemistry, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.
Scope of the CPG
The 2014 NSTE-ACS CPG is a full revision of the 2007 ACCF/AHA CPG for the management of patients with unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) and the 2012 focused update. 9 The new title, "Non-ST-Elevation Acute Coronary Syndromes," emphasizes the continuum between UA and NSTEMI. At presentation, patients with UA and NSTEMI can be indistinguishable and are therefore considered together in this CPG.
In the United States, NSTE-ACS affects >625 000 patients annually,* or almost three fourths of all patients with acute coronary syndrome (ACS). 10 In selecting the initial approach to care, the term "ischemia-guided strategy" has replaced the previous descriptor, "initial conservative management," to more clearly convey the physiological rationale of this approach.
The task of the 2014 GWC was to establish a contemporary CPG for the optimal management of patients with NSTE-ACS. It incorporates both established and new evidence from published clinical trials, as well as information from basic science and comprehensive review articles. These recommendations were developed to guide the clinician in improving outcomes for patients with NSTE-ACS. Table 2 lists documents deemed pertinent to this effort and is intended for use as a resource, thus obviating the need to repeat extant CPG recommendations.
The GWC abbreviated the discussion sections to include an explanation of salient information related to the recommendations. In contrast to textbook declaratory presentations, explanations were supplemented with evidence tables. The GWC also provided a brief summary of the relevant recommendations and references related to secondary prevention rather than detailed reiteration. Throughout, the goal was to provide the clinician with concise, evidence-based contemporary recommendations and the supporting documentation to encourage their application.
Overview of ACS
ACS has evolved as a useful operational term that refers to a spectrum of conditions compatible with acute myocardial ischemia and/or infarction that are usually due to an abrupt reduction in coronary blood flow ( Figure 1 ). 
Initial Evaluation and Management: Recommendations

Clinical Assessment and Initial Evaluation
Class
Prognosis-Early Risk Stratification
See Figure 2 and Table 3 for estimation at presentation of death and nonfatal cardiac ischemic events. See Table 4 for a summary of recommendations from this section. 
Class
Cardiac Biomarkers and the Universal Definition of Myocardial Infarction
See Table 5 for a summary of recommendations from this section.
Biomarkers: Diagnosis
Class I 
Cardiac-specific troponin (troponin I or T when a contemporary assay is used) levels should be mea-
Discharge From the ED or Chest Pain Unit
Class IIa
It is reasonable to observe patients with symptoms consistent with ACS without objective evidence of myocardial ischemia (nonischemic initial ECG and normal cardiac troponin) in a chest pain unit or telemetry unit with serial ECGs and cardiac troponin at 3-to 6-hour intervals. 90-94 (Level of Evidence: B) 2. It is reasonable for patients with possible ACS who have normal serial ECGs and cardiac troponins to have a treadmill ECG 93-95 (Level of Evidence: A)
, stress myocardial perfusion imaging, 93 or stress echocardiography 96,97 before discharge or within 72 hours after discharge. (Level of Evidence: B)
In patients with possible ACS and a normal ECG, normal cardiac troponins, and no history of coronary artery disease (CAD), it is reasonable to initially perform (without serial ECGs and troponins) coronary computed tomography angiography to assess coronary artery anatomy 98-100 (Level of Evidence: A) or rest myocardial perfusion imaging with a technetium-99m radiopharmaceutical to exclude myocardial ischemia. 101,102 (Level of Evidence: B) 4. It is reasonable to give low-risk patients who are referred for outpatient testing daily aspirin, short-acting nitroglycerin, and other medication if appropriate (eg, beta blockers), with instructions about activity level and clinician follow-up. (Level of Evidence: C)
Early Hospital Care: Recommendations
See Table 6 for a summary of recommendations from this section.
Standard Medical Therapies
Oxygen
Class I 1. Supplemental oxygen should be administered to patients with NSTE-ACS with arterial oxygen saturation less than 90%, respiratory distress, or other highrisk features of hypoxemia. (Level of Evidence: C)
Nitrates
Patients with NSTE-ACS with continuing isch-
Nitrates should not be administered to patients with NSTE-ACS who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. 112-114 (Level of Evidence: B)
Analgesic Therapy
Class IIb 1. In the absence of contraindications, it may be reasonable to administer morphine sulfate intravenously to patients with NSTE-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. 115 
,116 (Level of Evidence: B)
Class III: Harm
Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization for NSTE-ACS because of the increased risk of MACE associated with their use. 117,118 (Level of Evidence: B)
Beta-Adrenergic Blockers
Class I 1.
Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (eg, PR interval >0.24 second, second-or thirddegree heart block without a cardiac pacemaker, active asthma, or reactive airway disease). 119 
Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS
Initial Oral and Intravenous Antiplatelet Therapy in Patients With Definite or Likely NSTE-ACS Treated With an Initial Invasive or Ischemia-Guided Strategy
See Table 7 for a summary of recommendations from this section.
Class I ‡ See Table 7 for a summary of recommendations from this section.
Initial Parenteral Anticoagulant Therapy in Patients With Definite NSTE-ACS
Class I ‡ 1. In patients with NSTE-ACS, anticoagulation, in addition to antiplatelet therapy, is recommended for all patients irrespective of initial treatment strategy. Treatment options include: 
Ischemia-Guided Strategy Versus Early Invasive Strategies
See Figure 3 for the management algorithm for ischemiaguided versus early invasive strategy.
Early Invasive and Ischemia-Guided Strategies
For definitions of invasive and ischemia-guided strategies, see Table 8 . ||The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily. 144 ‡See 
An urgent/immediate invasive strategy (diagnostic angiography with intent to perform revascularization if appropriate based on coronary anatomy) is indicated in patients (men and women ¶) with NSTE-ACS
Risk Stratification Before Discharge for Patients
With an Ischemia-Guided Strategy of NSTE-ACS Class I Class IIa #Patients should receive a loading dose of prasugrel provided that they were not pretreated with another P2Y 12 receptor inhibitor.
Noninvasive stress testing is recommended in lowand intermediate-risk patients who have been free of ischemia at rest or with low-level activity for a minimum of 12 to 24 hours. 179-183 (Level of Evidence: B) 2. Treadmill exercise testing is useful in patients able to exercise in whom the ECG is free of resting ST changes that may interfere with interpretation. 179-182 (Level of Evidence: C) 3. Stress testing with an imaging modality should be used in patients who are able to exercise but have ST changes on resting ECG that may interfere with interpretation. In patients undergoing a low-level exercise test, an imaging modality can add prognostic information. 179-182 (Level of Evidence: B) 4. Pharmacological stress testing with imaging is recommended when physical limitations preclude adequate exercise stress. (Level of Evidence: C) 5. A noninvasive imaging test is recommended to evalu
It is reasonable to choose ticagrelor over clopidogrel for P2Y 12 inhibition treatment in patients with NSTE-ACS treated with an early invasive strategy and/or coronary stenting. 147,148 (Level of Evidence: B) 2. It is reasonable to choose prasugrel over clopidogrel for P2Y 12 treatment in patients with NSTE-ACS who
||The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily. 144 December 23/30, 2014 undergo PCI who are not at high risk of bleeding complications. 172 
,205 (Level of Evidence: B) 3. In patients with NSTE-ACS and high-risk features (eg, elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GP llb/llla inhibitor (abciximab, dou
PCI-GP IIb/IIIa Inhibitors
Class I 1. In patients with NSTE-ACS and high-risk features (eg, elevated troponin) and not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. 201-204 (Level of Evidence: A)
Class IIa
In patients with NSTE-ACS and high-risk features (eg, elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. 206,207 (Level of Evidence: B)
Anticoagulant Therapy in Patients Undergoing PCI
See Table 9 for dosing information on dosing of parenteral anticoagulants during PCI. 
Class I 1. An anticoagulant should be administered to patients with NSTE-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. (Level of Evidence: C) 2. Intravenous UFH is useful in patients with
Timing of Urgent Coronary Artery Bypass Graft in Patients With NSTE-ACS in Relation to Use of Antiplatelet Agents
Class I
Non-enteric-coated aspirin (81 mg to 325 mg daily) should be administered preoperatively to patients undergoing coronary artery bypass graft (CABG). 226-228 (Level of Evidence: B) 2. In patients referred for elective CABG, clopidogrel
and ticagrelor should be discontinued for at least 5 days before surgery 24,229-231 (Level of Evidence: B) and prasugrel for at least 7 days before surgery. 9 should be discontinued for at least 2 to 4 hours before surgery 236, 237 and abciximab for at least 12 hours before to limit blood loss and transfusion. 238 
(Level of Evidence: B)
Class IIb 1. In patients referred for urgent CABG, it may be reasonable to perform surgery less than 5 days after clopidogrel or ticagrelor has been discontinued and less than 7 days after prasugrel has been discontinued. (Level of Evidence: C)
Late Hospital Care, Hospital Discharge, And Posthospital Discharge
Care: Recommendations
Medical Regimen and Use of Medications at Discharge
Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization.
Titration of the doses may be required. 239 : B) 3. In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y 12 inhibitor therapy should be given for at least 12 months. 169 Options include: 
Risk Reduction Strategies for Secondary Prevention
Class I Class IIb 1. NSAIDs with increasing degrees of relative cyclooxygenase-2 selectivity may be considered for pain #Patients should receive a loading dose of prasugrel provided that they were not pretreated with another P2Y 12 receptor inhibitor.
||The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily. 144 relief only for situations in which intolerable discomfort persists despite attempts at stepped-care therapy with acetaminophen, nonacetylated salicylates, tramadol, small doses of narcotics, or nonselective NSAIDs. In all cases, use of the lowest effective doses for the shortest possible time is encouraged. 117 
Special Patient Groups: Recommendations
See Table 10 for summary of recommendations for this section.
NSTE-ACS in Older Patients
Class I 1. Older patients** with NSTE-ACS should be treated with GDMT, an early invasive strategy, and revascularization as appropriate. 269 There is no benefit of routine blood transfusion in hemodynamically stable patients with hemoglobin levels >8 g/dL III: No Benefit B 321-325
Cocaine and methamphetamine users
Manage patients with recent cocaine or methamphetamine use similarly to those without cocaine-or methamphetamine-related NSTE-ACS. The exception is in patients with signs of acute intoxication (eg, euphoria, tachycardia, and hypertension) and beta-blocker use unless patients are receiving coronary vasodilator therapy
Diabetes Mellitus
Class I Prophylactic anticoagulation may be considered to prevent LV thrombi IIb C N/A *Provocative testing during invasive coronary angiography (eg, using ergonovine, acetylcholine, methylergonovine) is relatively safe, especially when performed in a controlled manner by experienced operators. However, sustained spasm, serious arrhythmias, and even death can also occur but very infrequently. Therefore, provocative tests should be avoided in patients with significant left main disease, advanced 3-vessel disease, presence of high-grade obstructive lesions, significant valvular stenosis, significant LV systolic dysfunction, and advanced HF.
ACE indicates angiotensin-converting enzyme; ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; COR, Class of Recommendation; CPG, clinical practice guideline; CrCl, creatinine clearance; CVD, cardiovascular disease; DM, diabetes mellitus; GDMT, guideline-directed medical therapy; GP, glycoprotein; HF, heart failure; lABP, intra-aortic balloon pump; LOE, Level of Evidence; LV, left ventricular; MRI, magnetic resonance imaging; N/A, not available; NSTE-ACS, non-ST-elevation acute coronary syndrome; NTG, nitroglycerin; PCI, percutaneous coronary intervention; and UFH, unfractionated heparin. 
Class IIa
1. An invasive strategy is reasonable in patients with mild (stage 2) and moderate (stage 3) CKD. 307 
Summary and Evidence Gaps
Despite landmark advances in the care of patients with NSTE-ACS since the publication of the 2007 UA/NSTEMI CPG, 362 many emerging diagnostic and therapeutic strategies have posed new challenges. There is general acceptance of an early invasive strategy for patients with NSTE-ACS in whom significant coronary vascular obstruction has been precisely quantified. Low-risk patients with NSTE-ACS are documented to benefit substantially from GDMT, but this is often suboptimally used. Advances in noninvasive testing have the potential to identify patients with NSTE-ACS who are at intermediate risk and are candidates for invasive versus medical therapy. Newer, more potent antiplatelet agents in addition to anticoagulant therapy are indicated irrespective of initial treatment strategy. Evidence-based decisions will require comparative-effectiveness studies of available and novel agents. The paradox of newer and more potent antithrombotic and anticoagulant drugs that reduce major adverse cardiac outcomes but increase bleeding risk occurs with greater frequency in patients with atrial fibrillation. Patients with atrial fibrillation who develop NSTE-ACS and receive a coronary stent are the population at risk from triple anticoagulant/antiplatelet therapy. This regimen has been reported to be safely modified by elimination of aspirin, a finding that requires confirmation.
Among the most rapidly evolving areas in NSTE-ACS diagnosis is the use of cardiac troponin, the preferred biomarker of myocardial necrosis. Although a truly high-sensitivity cardiac troponin is not available in the United States at the time this CPG was prepared, the sensitivity of contemporary assays continues to increase. This change is accompanied by higher rates of elevated cardiac troponin unrelated to coronary plaque rupture. The diagnostic quandary posed by these findings necessitates investigation to elucidate the optimal utility of this advanced biomarker. A promising approach to improve the diagnostic accuracy for detecting myocardial necrosis is measurement of absolute cardiac troponin change, which may be more accurate than the traditional analysis of relative alterations.
Special populations are addressed in this CPG, the most numerous of which are older persons and women. More than half of the mortality in NSTE-ACS occurs in older patients, and this high-risk cohort will increase as our population ages. An unmet need is to more clearly distinguish which older patients are candidates for an ischemia-guided strategy compared with an early invasive management strategy. An appreciable number of patients with NSTE-ACS have angiographically normal or nonobstructive CAD, a group in which women predominate. Their prognosis is not benign and the multiple mechanisms of ACS postulated for these patients remain largely speculative. Clinical advances are predicated on clarification of the pathophysiology of this challenging syndrome.
A fundamental aspect of all CPGs is that these carefully developed, evidence-based documents cannot encompass all clinical circumstances, nor can they replace the judgment of individual physicians in management of each patient. The science of medicine is rooted in evidence, and the art of medicine is based on the application of this evidence to the individual patient. This CPG has adhered to these principles for optimal management of patients with NSTE-ACS. 
